The Announcement ‍and Its Details

On november 6,‍ 2024, Donald Trump, while campaigning in Council Bluffs, iowa, unveiled a plan to lower the cost of weight loss drugs, specifically mentioning Wegovy and Zepbound as reported by STAT News. The proposal aims to provide lower prices for Medicare and Medicaid beneficiaries, and also individuals paying out-of-pocket. The announcement lacked specific details regarding how these lower prices would be achieved.

Trump stated the deal ‍would involve negotiating with pharmaceutical companies to secure discounts, ⁤but the specifics of these negotiations remain unclear. STAT News highlighted several unanswered questions surrounding the plan, including the extent of the discounts and the timeline for implementation.

The Role ‍of the Inflation Reduction Act

Notably, the Trump administration did not mention the Inflation Reduction Act (IRA) during the announcement.⁣ Trump has consistently criticized the ⁢IRA,particularly its ⁤provision allowing Medicare to negotiate drug prices,and no Republicans⁤ supported ‍the legislation when ‍it passed in 2022. However, health ⁣policy⁤ experts suggest the IRA may have inadvertently created conditions that make Trump’s deal possible.

Stacie Dusetzina, a health policy⁢ professor at Vanderbilt University Medical Center, explained ‍that the IRA’s negotiation ‍program has already begun to shift the landscape⁤ of drug pricing.”The IRA created a new benchmark for drug prices,” Dusetzina⁣ stated.⁤ “Drug companies are now more willing to consider ‍discounts to avoid having their products subject to negotiation.” This⁤ shift in willingness ⁢could make Trump’s proposed negotiations⁤ more fruitful.

othre experts ‍echo this sentiment. Loren Adler, associate director of the USC-Brookings Schaeffer Initiative for health Policy, believes the IRA’s threat of negotiation gives the administration leverage.”The IRA is ‍a powerful tool,even if the‍ current administration doesn’t want to acknowledge it,” Adler said. KFF provides further context on the potential⁣ interplay between the two approaches.

Impact on Medicare and Medicaid

The potential impact⁣ of‍ Trump’s plan on‍ Medicare and Medicaid is ⁢significant. Weight loss drugs like Wegovy and Zepbound can cost over $1,300 per ⁤month, making them inaccessible to many individuals. Lowering these costs could dramatically increase access to these medications,potentially improving public health outcomes.

Here’s a⁤ breakdown of potential beneficiaries: